GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials.
Xiaoming JiaMahboob AlamYumei YeMandeep BajajYochai BirnbaumPublished in: Cardiovascular drugs and therapy (2019)
Overall, GLP-1R agonists appear to have cardioprotective properties likely via modification of metabolic parameters such as glycemic control, weight loss, and improvement in blood pressure. Additional studies are warranted to compare cardiovascular outcomes among the different agents.
Keyphrases
- glycemic control
- weight loss
- cardiovascular disease
- type diabetes
- blood pressure
- blood glucose
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- left ventricular
- hypertensive patients
- insulin resistance
- case control
- obese patients
- heart failure
- cardiovascular risk factors
- weight gain
- cardiovascular events
- skeletal muscle